Latest Property Portfolio News

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Harvey Norman Holdings detailed its expansive international growth and omni-channel strategy at its 2025 AGM, highlighting new flagship stores and AI-driven retail innovations across eight countries.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Alterity Therapeutics announces significant board changes, including the retirement of founding chairman Geoffrey Kempler and appointment of CEO Dr David Stamler as Managing Director, aligning leadership with its Phase 3 clinical ambitions.

Autosports Group Limited reports record FY25 revenue and profit, while announcing a strategic acquisition of 10 Barry Bourke Motors dealerships in Victoria, signaling robust growth momentum into FY26.

Oceania Healthcare reports a robust interim result for the six months to September 2025, with significant earnings growth, improved sales, and a reduction in debt gearing. The company’s strategic focus on cost control, capital management, and sustainable care delivery underpins its positive outlook despite housing market headwinds.

Charter Hall Group reported solid FY25 financial results with significant earnings growth and sustainability milestones, while guiding higher earnings and distributions for FY26.

CVC Limited has released a replacement prospectus for its $75 million CVC Notes 3 offer, combining a New Money Offer and a Reinvestment Offer for existing CVCHA holders. The notes aim to support CVC’s capital management and real estate investment strategy.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Desane Group Holdings posted a $3.3 million net profit for FY25, bolstered by key lease extensions and a $6.2 million property valuation uplift despite ongoing post-pandemic challenges.

Archer Materials has partnered with CSIRO to develop cutting-edge quantum machine learning models aimed at revolutionizing fraud detection in financial transactions.